Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Prebiotic Adjuvants for Cancer Immunotherapy
EF 2019-20
Résumé
"Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1), which reinvigorate the immune system to attack cancerous cells, have revolutionized treatments in oncology. While these therapeutics work phenomenally well for some individuals, the majority of patients fail to respond to these therapies. One of the causes of this lack of response lies in the gut microbiota, the complex ecosystem of microorganisms in the gastrointestinal tract. Recent investigations have shown that the gut microbiota can be modulated to improve the efficacy of PD-1 inhibitors in mice. Our research program aims to discover and identify prebiotics, which are molecules that are metabolized by the gut microbiota, that change the composition of the microbiota towards that of responders to PD-1 therapy. We hypothesize that prebiotics can favor the growth of immune-stimulating bacteria to improve the efficacy of PD-1 inhibitors in a mouse model of cancer. Plants contain molecules that are known to exert beneficial prebiotic effects in combination with PD-1 inhibitors in cancer models. However, we don't yet know which molecules are responsible for these effects. Our first objective will be to discover the identity of these molecules. In parallel, we will answer the question of ""who eats what?"" among bacteria overrepresented in PD-1 responding patients in order to better identify candidate prebiotics. We will then evaluate the efficacy of these candidate molecules in a mouse model of cancer in combination with PD-1 therapy. Currently, cancer is the leading cause of death in Canada. The combined administration of prebiotics and PD-1 inhibitors represents a novel strategy that would allow a greater proportion of patients to benefit from this revolutionary cancer therapy. "
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
429147
Name
Pidgeon Reilly C
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Prebiotic Adjuvants for Cancer Immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug Response; Glycans; Immune-Checkpoint Inhibitors; Microbiome; Modulation; Mouse Model; Natural Products; Pd-1; Polyphenols; Prebiotics
Abstract
"Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1), which reinvigorate the immune system to attack cancerous cells, have revolutionized treatments in oncology. While these therapeutics work phenomenally well for some individuals, the majority of patients fail to respond to these therapies. One of the causes of this lack of response lies in the gut microbiota, the complex ecosystem of microorganisms in the gastrointestinal tract. Recent investigations have shown that the gut microbiota can be modulated to improve the efficacy of PD-1 inhibitors in mice. Our research program aims to discover and identify prebiotics, which are molecules that are metabolized by the gut microbiota, that change the composition of the microbiota towards that of responders to PD-1 therapy. We hypothesize that prebiotics can favor the growth of immune-stimulating bacteria to improve the efficacy of PD-1 inhibitors in a mouse model of cancer. Plants contain molecules that are known to exert beneficial prebiotic effects in combination with PD-1 inhibitors in cancer models. However, we don't yet know which molecules are responsible for these effects. Our first objective will be to discover the identity of these molecules. In parallel, we will answer the question of ""who eats what?"" among bacteria overrepresented in PD-1 responding patients in order to better identify candidate prebiotics. We will then evaluate the efficacy of these candidate molecules in a mouse model of cancer in combination with PD-1 therapy. Currently, cancer is the leading cause of death in Canada. The combined administration of prebiotics and PD-1 inhibitors represents a novel strategy that would allow a greater proportion of patients to benefit from this revolutionary cancer therapy. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pidgeon, Reilly C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~